Stockscreener 앱 받기
70.98
1.47%
-1.06
전일 마감가:
$72.04
열려 있는:
$71.71
하루 거래량:
2.23M
Relative Volume:
1.05
시가총액:
$8.35B
수익:
$947.36M
순이익/손실:
$392.47M
주가수익비율:
23.50
EPS:
3.02
순현금흐름:
$392.71M
1주 성능:
-10.65%
1개월 성능:
+0.78%
6개월 성능:
-0.21%
1년 성능:
+23.57%
1일 변동 폭
$70.56
$72.72
1주일 범위
$70.56
$81.51
52주 변동 폭
$47.50
$82.22
Halozyme Therapeutics Inc Stock (HALO) Company Profile
명칭
Halozyme Therapeutics Inc
전화
(858) 794-8889
주소
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
70.98 | 8.47B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.90 | 119.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.67 | 82.71B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
844.41 | 52.43B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
336.19 | 45.01B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
362.14 | 39.23B | 4.98B | 69.60M | 525.67M | 0.5198 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-10-14 | 업그레이드 | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-05-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | 다운그레이드 | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-06-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | 개시 | TD Cowen | Outperform |
| 2023-07-24 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-24 | 개시 | H.C. Wainwright | Buy |
| 2023-05-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Berenberg | Buy |
| 2023-03-16 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | 재개 | Morgan Stanley | Overweight |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 개시 | Evercore ISI | Outperform |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | 재확인 | The Benchmark Company | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-07-01 | 개시 | The Benchmark Company | Buy |
| 2020-02-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Buy |
| 2019-11-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-10-19 | 재개 | Piper Jaffray | Neutral |
| 2018-05-11 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-16 | 재확인 | Piper Jaffray | Overweight |
| 2017-01-06 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-11-18 | 개시 | Citigroup | Buy |
| 2015-09-22 | 개시 | Barclays | Overweight |
| 2015-06-22 | 재확인 | JP Morgan | Overweight |
| 2015-03-03 | 재확인 | UBS | Buy |
| 2015-02-18 | 재확인 | MLV & Co | Buy |
| 2015-01-08 | 재확인 | MLV & Co | Buy |
모두보기
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
Halozyme outlines $1.71B–$1.81B 2026 revenue target as new subcutaneous technologies expand pipeline - MSN
Stock Report: Is Halozyme Therapeutics Inc forming a breakout patternEarnings Miss & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Halozyme Therapeutics (NASDAQ:HALO) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Jupiter Asset Management Ltd. Purchases 129,971 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics Reports Significant 2025 Growth - National Today
Halozyme Therapeutics Reports Q4 Earnings - National Today
Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $90.00 - MarketBeat
Benchmark Raises Target Price for HALO, Maintains Buy Rating | H - GuruFocus
Demystifying Halozyme Therapeutics: Insights From 4 Analyst Reviews - Benzinga
Benchmark raises Halozyme stock price target to $90 on strong results - Investing.com Nigeria
Benchmark raises Halozyme stock price target to $90 on strong results By Investing.com - Investing.com South Africa
Halozyme (HALO) loses 9% on weak earnings - MSN
Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $75.00 at Wells Fargo & Company - MarketBeat
Wells Fargo Raises Price Target on Halozyme Therapeutics (HALO) to $75 | HALO Stock News - GuruFocus
Halozyme (HALO) Loses 9% on Weak Earnings - Finviz
Halozyme Therapeutics (NASDAQ:HALO) Trading Down 8.7% on Disappointing Earnings - Defense World
TD Cowen raises Halozyme stock price target on royalty growth By Investing.com - Investing.com Nigeria
Why Halozyme Therapeutics (HALO) Is Down 7.9% After Acquisition-Driven Q4 Loss And 2026 Outlook Reaffirmation - Yahoo Finance
Halozyme Earnings Call Highlights Royalty-Fueled Growth - TipRanks
Halozyme Therapeutics (HALO) Reports Q4 Earnings Miss - GuruFocus
Halozyme shares slide as surprise Q4 loss and acquisition-related charges overshadow revenue beat - Quiver Quantitative
Halozyme Therapeutics (NASDAQ:HALO) Stock Price Down 8.7% Following Weak Earnings - MarketBeat
Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues - Nasdaq
Is Halozyme Therapeutics (HALO) Stock Price Out Of Step With Recent Valuation Signals - Yahoo Finance
TD Cowen raises Halozyme stock price target on royalty growth - Investing.com South Africa
Halozyme Delivers Record FY2025 As 2026 Sets Up A Major Profitability Surge (NASDAQ:HALO) - Seeking Alpha
Halozyme Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2025 Earnings Call Transcript - Insider Monkey
Halozyme Therapeutics, Inc. $HALO Shares Sold by Hodges Capital Management Inc. - MarketBeat
Halozyme Therapeutics Inc (HALO) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
Decoding Halozyme Therapeutics Inc (HALO): A Strategic SWOT Insi - GuruFocus
Halozyme Therapeutics Q4 2025 Earnings Call Highlights - Intellectia AI
Halozyme Q4 2025 Earnings Surge: Royalty Revenue Soars 52% - AlphaStreet News
Halozyme Therapeutics Q4 Earnings Call Highlights - MarketBeat
Halozyme Therapeutics (HALO) Reports Robust Growth in 2025 Earni - GuruFocus
Halozyme Therapeutics (NASDAQ:HALO) Announces Quarterly Earnings Results, Misses Expectations By $2.16 EPS - MarketBeat
Here's What Key Metrics Tell Us About Halozyme Therapeutics (HALO) Q4 Earnings - Yahoo! Finance Canada
Halozyme (HALO) Q4 2025 Earnings Call Transcript - The Globe and Mail
Halozyme 2025 Earnings: Revenue Up 51.6%, Guides for 2026 EPS of $8News and Statistics - IndexBox
Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
HALO Reaffirms Strong FY26 Revenue and EBITDA Growth Forecast - GuruFocus
(HALO) Halozyme Expects Full Year 2026 Revenue Range $1.71B$1.81B, vs. FactSet Est of $1.76B - marketscreener.com
Halozyme Therapeutics (NASDAQ:HALO) Surprises With Q4 CY2025 Sales - Finviz
Earnings Flash (HALO) Halozyme Therapeutics Posts Q4 Revenue $451.8M, vs. FactSet Est of $435.7M - marketscreener.com
Earnings Flash (HALO) Halozyme Therapeutics Posts Q4 Adjusted Loss $0.24, vs. FactSet Est of $2.16 Income - marketscreener.com
Halozyme Therapeutics: Fourth Quarter Earnings Overview - Bitget
Halozyme shares fall 4% following surprise Q4 loss - Investing.com Australia
Halozyme Therapeutics: Q4 Earnings Snapshot - marketscreener.com
HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE - PR Newswire
Halozyme earnings in focus: Can royalty momentum carry into 2026? By Investing.com - Investing.com Australia
Halozyme earnings in focus: Can royalty momentum carry into 2026? - Investing.com
Halozyme Therapeutics Inc (HALO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Halozyme Therapeutics Inc 주식 (HALO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER |
Feb 16 '26 |
Option Exercise |
0.00 |
23,773 |
0 |
40,231 |
| Torley Helen | PRESIDENT AND CEO |
Feb 16 '26 |
Option Exercise |
0.00 |
89,055 |
0 |
777,336 |
| Torley Helen | PRESIDENT AND CEO |
Feb 03 '26 |
Option Exercise |
12.07 |
20,000 |
241,400 |
728,719 |
| Torley Helen | PRESIDENT AND CEO |
Feb 04 '26 |
Option Exercise |
12.07 |
20,000 |
241,400 |
728,719 |
| Torley Helen | PRESIDENT AND CEO |
Feb 05 '26 |
Option Exercise |
12.07 |
10,000 |
120,700 |
718,719 |
| Torley Helen | PRESIDENT AND CEO |
Feb 04 '26 |
Sale |
77.24 |
20,000 |
1,544,820 |
708,719 |
| Torley Helen | PRESIDENT AND CEO |
Feb 03 '26 |
Sale |
76.12 |
20,000 |
1,522,317 |
708,719 |
| Torley Helen | PRESIDENT AND CEO |
Feb 05 '26 |
Sale |
78.64 |
10,000 |
786,366 |
708,719 |
0.34%
0.89%
자본화:
|
볼륨(24시간):